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Objective: Outcome reporting bias (ORB) is a threat to validity of systematic reviews. Multivariate 
meta-analysis (MVMA) can potentially reduce the impact of ORB when outcomes are correlated. 
The aim of this study was to assess ORB in Cochrane systematic reviews of rheumatoid arthritis, 
and to demonstrate how MVMA may examine its impact.   
 
Study Design and Setting: Reviews were assessed for ORB in relation to eight outcomes for 
rheumatoid arthritis using a nine-point classification system. Impact of ORB was assessed by 
comparing estimates from univariate and MVMA models. 
 
Results: ORB assessment was applied in 21 included reviews, and all contained missing data on 
at least one of the eight outcomes. ORB was highly suspected in 247 (22%) of the 1118 evaluable 
outcomes from 155 assessable trials. MVMA and univariate results sometimes differed importantly.  
The maximum change in treatment effect estimate between MVMA and univariate approach was 
found to be 176% for one of the outcome considered.  
 
Conclusions: ORB has the potential to affect the conclusions in meta-analyses. This could be 
avoided if trialists reported on all measured outcomes in full. If missing outcome data are 
unobtainable, MVMA is useful to examine the impact of missing outcomes and ORB on 
conclusions.  
 
 
 
 
 
 
 
 
 
 
 
 
What is new? 
 
Key findings 
 
• All 21 reviews considered contained missing data from the included primary studies in at 
least one outcome. High suspicion outcome reporting bias was suspected in nearly a 
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1. Introduction 
Selective outcome reporting occurs when a subset of the originally recorded outcome variables in a 
trial are selectively reported in a publication based on their results. When outcome reporting is 
driven by the significance and/or direction of the effect size (e.g. non-significant outcomes are 
reported only as p-value>0.05, or are suppressed altogether), we refer to this as Outcome 
Reporting Bias (ORB) [1]. Empirical evidence has shown that outcomes which are statistically 
significant are more likely to be fully reported compared to non-significant outcomes [2]. Findings 
from the ORBIT (Outcome Reporting Bias in Trials) study have shown that over a half of reviews 
did not include full data for a single review primary outcome of interest from all eligible trials and 
half of the trials assessed with missing data were under high suspicion of ORB [3]. Related work 
looking at all published reviews from the Cochrane Cystic Fibrosis group revealed that all of the 
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eligible trials did not include full data when looking across all review outcomes, i.e. both primary 
and secondary outcomes [4].  
 
One way to reduce the problem of ORB is the introduction of an agreed minimum set of 
standardised outcomes, to be measured and reported in all trials for a particular disease or 
condition, referred to as a ‘Core Outcome Set’ (COS) [5]. In 1994, the OMERACT (Outcome 
Measures in Rheumatology) group, aided by meetings of experts from international organisations, 
ratified one of the first core outcome sets for rheumatoid arthritis [6]: tender joints, swollen joints, 
pain, physical global assessment, patient global assessment, function and acute phase reactants. 
In studies lasting at least one year, an additional recommendation was that radiographs of the 
joints to be taken to assess radiological damage.  
 
An observational review of rheumatology trials published up to 2009 has suggested that between 
60-70% of trialists conducting trials in rheumatoid arthritis measured the rheumatoid arthritis core 
outcomes [7]. Encouragingly, 90% of trialists contacted said they would consider measuring the 
rheumatoid arthritis core outcome set if they were to lead a new trial in rheumatoid arthritis. 
Nevertheless, knowing that an outcome was measured in a trial does not necessarily constitute 
appropriate reporting in the trial publication. Another problem in rheumatology trials is that 
composite outcomes are often reported in place of the individual core outcomes; examples include 
Disease Activity Score [8] and American College of Rheumatology criteria [9]. The consequence of 
this type of reporting is that many meta-analyses of the individual core outcomes will contain 
missing data, when it is known that the individual outcomes were measured and possibly analysed.  
If ORB is suspected in a review, and missing data are unobtainable from trial authors, a sensitivity 
analysis should be considered to determine how robust meta-analysis conclusions are to ORB. 
Review conclusions that are not robust to ORB may need to be amended because the treatment 
effect estimates can be overestimated as non-significant outcome data are supressed from the 
analyses. The maximum bias bound [10]; a multivariate meta-analysis (MVMA) approach [11] and 
a model-based correction method [1] are three such sensitivity analysis approaches that have been 
used to assess robustness of the meta-analysis results. The model-based correction method offers 
a more elegant technique for adjusting for ORB than the maximum bias bound approach as the 
mechanism for bias is modelled directly [1].  However, both these methods can only be applied to 
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single outcomes whereas the MVMA approach can be applied to multiple outcomes, which is an 
optimal approach when considering the simultaneous adjustment of bias in a core outcome set.  In 
this paper we consider only the MVMA approach.         
 
The MVMA approach jointly syntheses multiple correlated outcomes [10], such as the core set of 
outcomes for rheumatoid arthritis. For example, patients with swollen joints might experience more 
pain, such that there is a positive correlation between the outcomes swollen joints and pain. It has 
been shown both analytically [12] and through simulation and application [11] that utilising the 
correlation allows one to ‘borrow strength’ across outcomes; in other words, one can learn about 
unreported outcomes through the reported results for other correlated outcomes. For this reason, 
MVMA can produce summary treatment effect estimates that are different to those from a 
traditional 'univariate' meta-analysis of each outcome separately. This is especially important when 
there are missing outcomes across studies due to ORB [11]. 
 
The aims of this current study were to determine the prevalence of ORB in trials included in 
Cochrane systematic reviews of rheumatoid arthritis by considering all eight outcomes in the core 
outcome set; and to illustrate the use of the MVMA method. This is the first study to assess ORB in 
reviews against a core outcome set. We also illustrate the potential benefit of the MVMA approach 
by applying it to one of the reviews where ORB is likely and the outcomes under consideration 
have strong correlations. This is particularly important as a previous study which compared 
univariate meta-analysis with multivariate meta-analysis led the authors to conclude that the choice 
between univariate and multivariate meta-analysis had unclear or limited practical importance [13].     
 
2. Methods 
A cohort of systematic reviews published by the Cochrane Musculoskeletal Group (up to and 
including the September 2012 issue) that considered pharmacological interventions [disease 
modifying anti-rheumatic drugs (DMARDs), biologics or glucocorticoids] for the treatment of 
rheumatoid arthritis were included. Reviews were identified by JJK via the Cochrane topics link 
(http://onlinelibrary.wiley.com/book/10.1002/14651858/topics) and were those that were indexed 
under ‘Musculoskeletal’, ‘Rheumatoid Arthritis’, ‘Treatment [Pharmacological Interventions]’ and 
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‘Biologics/Steroids/DMARDs’. Selections were checked by GF. The scope of the COS was not 
specifically designed for non-drug trials and does not focus on measures of safety; reviews were 
therefore excluded if they considered non-pharmacological interventions or considered drug safety 
only. Overviews and reviews that contained no eligible randomised controlled trials (empty reviews) 
were also excluded, as an assessment of primary studies would not be possible.    
 
All reports for each randomised trial included in eligible reviews were obtained for evaluation. Trials 
that had been excluded in the ‘characteristics of excluded studies’ section were also checked for 
any suggestion of ORB. For example, if a review had excluded trials as a result of ‘no relevant 
outcome data’, then these trials were also scrutinised for the presence of ORB and included in the 
assessment. 
 
2.1 Assessing randomised controlled trials for ORB in systematic reviews 
The methodology for assessing ORB in trials follows that of the original ORBIT study [3]. An 
outcome matrix was constructed using the ORBIT matrix generator http://ctrc.liv.ac.uk/orbit/ for 
each review by listing all the eligible studies as rows and the eight core outcomes as columns in 
the matrix [14]. For each outcome, full, partial and no reporting were distinguished from the 
information provided in the review. One example matrix for this particular application is given in 
web appendix 1 (Table 1). All reports for each randomised trial, partially reporting or not reporting 
on at least one of the core outcomes were obtained and an assessment of the potential risk of ORB 
was made for each missing or incompletely reported core outcome using the nine-point 
classification system developed in the ORBIT study [3]. The classification system developed for 
this study is provided in Table 1.  The system identifies whether there is evidence that the outcome 
was measured and analysed but not reported in full (A to D), whether the outcome was measured 
but not necessarily analysed (E and F), if it is unclear whether the outcome was measured (G and 
H), or of it was clear the outcome was not measured (I). If composite outcome criteria were 
reported in full, but no data on any of the individual core outcomes were reported then the low risk 
F-classification was used for all core outcomes as it may not have been the trialists intention to 
analyse the individual core outcomes. If a trialist selectively reported some of the outcomes from 
the composite, then the high-risk E-classification was used for the core outcomes not reported, as 
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in this situation it is more likely that all of the core outcomes would have been analysed and the 
likely reason for some of them not being reported is a non-significant result. In some cases it is 
often problematic to assess whether an outcome was measured and clinical judgement is required. 
If there were any uncertainties with the classifications, review authors were consulted. All trials 
were independently classified by GF and JJK and disagreements were resolved through 
discussion. 
 
2.2 Assessing the impact of ORB using multivariate meta-analysis 
To illustrate the impact ORB may have in a review containing multiple outcomes, a multivariate 
meta-analysis approach was applied to a review comparing Auranofin with placebo for the 
treatment of rheumatoid arthritis [15]. The aim was to examine whether the summary results and 
conclusions from the multivariate meta-analysis differed to those from the original meta-analyses 
performed by the review authors. The impact was assessed in terms of the change in the treatment 
effect estimates, change in the statistical significance of the treatment effect estimates and change 
in the precision of the treatment effect estimates, for each of the outcomes of interest.  
 
First univariate fixed effect meta-analysis (UFMA) and multivariate fixed effect meta-analysis 
(MFMA) models were fitted, as the original review assumed fixed treatment effects for all 
outcomes. Secondly, univariate random effects meta-analysis (URMA) and multivariate random-
effects meta-analysis (MRMA) models were then fitted for comparison, on the basis that the review 
commented that in some cases heterogeneity existed, as assessed using I2 (I2 ranged from 0% to 
83% for the seven core outcomes meta-analysed).  
An analogous equivalent to the univariate I2 statistic which has been proposed for use in 
multivariate meta-analysis 
2
RI  was also computed [12]. Specifications for the bivariate fixed and 
random effects models are provided in Riley et al. [16] (the interpretation of random effects models 
is discussed by Higgins et al. [17]); these models were simply extended to the multivariate case 
[10] as described by Jackson et al. Web appendix 2 provides details of both the univariate and 
multivariate models in full, with technical details on how within-study and between-study correlation 
for the multiple outcomes was accounted for. In particular, within-study correlations (of the 
treatment effect estimates for the outcomes) were derived from the patient-level correlations 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
8 
 
amongst the outcomes as provided directly by one of the include trials. The model parameters 
were estimated using the ‘mvmeta’ module [18] in STATA using the method of maximum likelihood 
for fixed effects models and restricted maximum likelihood method for random-effects models. We 
did not consider radiological damage in our analyses, firstly because this outcome was not meta-
analysed in the original review and secondly as only two of the nine included trials were 52 weeks 
or longer in duration, meaning that there was no OMERACT recommendation to measure this 
outcome in the majority of trials included in this review.  
 
3. Results 
3.1 Assessment of systematic reviews 
3.1.1 Review eligibility 
The Cochrane Musculoskeletal Group published 56 unique rheumatoid arthritis reviews up to and 
including the September 2012 issue (Figure 1). Thirty-five reviews were excluded: 20 focused on 
non-pharmacological interventions, thirteen studied symptom modifying anti-rheumatic drugs, one 
was an overview and one focussed on safety. Of the remaining 21 reviews included in the 
assessment, 12 reviews considered disease modifying anti-rheumatic drugs (DMARDs), eight 
considered biologics and one considered glucocorticoids. All reviews required an ORB assessment 
for at least one eligible trial. The 21 reviews included a total of 172 trials for assessment (Figure 1).  
 
3.1.2 Trial assessed 
Among the 172 trials included within the 21 reviews, 17 trials could not be assessed further either 
because the articles were not in English (n=10) or the trial reports were unobtainable (n=7). 
Therefore, in our study we assessed 155 trials, 94 on DMARDs, 45 on biologics and 16 on 
glucocorticoids (Figure 1).  
 
3.2 Assessment results: classification according to ORBIT criteria 
Of the 155 assessable trials, 21 trials fully reported the outcome data for all core outcomes but the 
data in only 10 of these were adequately reported in the review. The ORBIT classifications for all 
the trials assessed are shown in Table 2. A breakdown of the classification by intervention class 
(DMARDs, biologics, and glucocosteroids) is provided in web appendix 1 (Table 2). 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
9 
 
At the trial level, missing or incomplete reporting of outcome data for each core outcome ranged 
from 36% (radiological damage 12 out of 33 trials with follow-up greater than 52 weeks) to 56% 
(physician global 87 out of 155 trials).   
 
For 515 (46%) of the 1118 evaluable outcomes in our study, the set of core outcomes was either 
partially reported or not reported (A to I classification) (Table 2). For 22% (247 of the 1118 
assessable outcomes), at least one core outcome was classified under high suspicion for outcome 
reporting bias (A, D, E, or G classification), while for 19% (212/1118), it was clear the outcomes 
were measured and analysed (A, B, C, D classification) but the reporting of the outcomes meant 
that the data could not be included in a meta-analysis.  
 
3.4 Application to the review of Auranofin for the treatment of rheumatoid arthritis  
We now consider one of the reviews in detail [15], which evaluated the evidence for Auranofin for 
the treatment of rheumatoid arthritis. Of the nine included trials in this review, none fully reported 
data on all the core outcomes according to OMERACT recommendation.  The amount of missing 
participant data from the original review meta-analysis ranged from 10% (acute phase reactant: 
ESR) to 66% (Function: HAQ). Table 3 shows the univariate (UFMA, URMA) meta-analysis and 
multivariate (MFMA, MRMA) meta-analysis results. The within-study correlation between treatment 
effects estimates for pairs of outcomes was often high and ranged between 0.18 (between swollen 
joints and acute phase reactant) and 0.91 (between pain and patient global) (web appendix1 (Table 
3)).    
 
Comparison of univariate and multivariate fixed effect results 
For Auranofin example, high risk ORB classifications were awarded to at least one trial where the 
MFMA approach provided a treatment estimate that demonstrated a smaller benefit in treatment, 
which indicates that the UFMA estimates might have been overestimated as a result of ORB. 
The UFMA model results were the same as those presented in the original review. When fitting the 
MFMA model, there was a reduction in standard errors for all outcomes ranging from 3% for APR 
to 49% for physician global. Of clinical importance, there was a shift in the pooled treatment effect 
for all of the core outcomes. For example, considering function (HAQ), the pooled mean difference 
was equal to -0.13 in the UFMA model compared with -0.16 in the MFMA model. The UFMA 
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estimate showed a benefit for Auranofin (-0.13 change) with a marginal non-significant result 
(p=0.066), but the MFMA indicates a larger difference between the treatment groups (-0.16 
change). As a consequence of the larger difference in treatment effect, coupled with the increased 
precision, the MFMA estimate was statistically significant (p=0.004). The shift in direction of the 
estimate when applying MFMA does not suggest ORB as the direction indicates a more positive 
result. In this example, for this particular outcome, it was unlikely that ORB was present as the 
studies not reporting on function were all classified as low risk ORB (H-classification). 
 
While there were no changes in statistical significance for any of the other outcomes between the 
UFMA and MFMA approaches, potentially clinical important differences were found between the 
treatment effect estimates. There were larger benefit differences in treatment effect favouring 
Auranofin using the MFMA approach for pain (0.06 difference) but smaller benefit differences in 
treatment effect for all the other outcomes; the largest difference was for swollen joints where the 
MFMA approach showed a 84% reduction on benefit (mean difference -0.290) for Auranofin when 
compared to the estimate from the URMA model (mean difference -0.047). The smallest change in 
the pooled treatment effect between the two models was for acute phase reactants (APR), where 
there was almost complete data. For APR the MRMA approach showed a 4% reduction on benefit 
(mean difference -9.040) for Auranofin when compared to the estimate from the URMA model 
(mean difference -8.723).  
  
Comparison of univariate and multivariate random effects results 
When we fitted the MRMA model, the 2RI  value was 83% indicating that across all outcomes, the 
total variation in the meta-analysis is mainly due to between-study heterogeneity; this suggests that 
the random-effects model might be the appropriate model to fit to these data. For the MRMA model 
we observed smaller standard errors and hence improved statistical precision for some, but not all, 
of the outcomes when compared to the URMA model. Some outcomes had lower precision of their 
summary effect in the MRMA because the between study variance estimates becoming larger than 
those from URMA. There was no change in statistical significance at the 5% level for any of the 
outcomes when comparing URMA with MRMA; however, as seen in the fixed effect results, the 
outcome function (HAQ) was closer to statistical significance (p=0.054) favouring Auranofin when 
applying the MRMA rather than URMA model. Also there remain large differences between the 
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summary treatment effect estimates when comparing URMA and MRMA (largest increase is equal 
to 176% for swollen joints). In contrast to the fixed effect models, neither of the global 
measurements (physician and patient) reaches statistical significance for either of URMA or 
MRMA, the likely result of the summary treatment effects having larger standard errors due to 
larger estimates of between-study heterogeneity. When we applied the MRMA, the summary 
treatment estimates moved towards the null for tender joints and pain where high suspicion ORB 
was suspected. The shift in treatment effect estimates was in the opposite direction for the global 
measurements (physician and patient), function and acute phase reactant. The impact of ORB was 
likely to be minimal for these outcomes.  
 
4. Discussion 
This is the first study to consider an assessment of outcome reporting bias against a well-
established core set of outcomes. The OMERACT core outcome set (sometimes referred to as 
ILAR [International League of Associations for Rheumatology] core set of outcomes) was ratified 
for use in clinical trials of rheumatoid arthritis but is also endorsed by the Cochrane 
Musculoskeletal Group [19]. While the uptake of the measurement of the core outcome set for 
rheumatoid arthritis trials has been shown to be increasing [7], the reporting of the outcomes for 
many of these remains insufficient, meaning that many meta-analyses are unable to include data 
from all relevant studies. Similar to the [4] study that looked at all review outcomes in a cohort of 
Cochrane Fibrosis reviews, all the reviews considered in this study included at least one study 
which contained missing data on at least one core outcome. Across all core outcomes, there were 
212 items of study data missing from meta-analyses for outcomes that were clearly measured and 
analysed but either not reported or reported inappropriately (A-D classifications), and a further 191 
items of study data were clearly measured or likely measured but not reported because of non-
significant results (E and G classifications). It is important that trialists follow CONSORT 2010 [20] 
(Consolidated Standards of Reporting Trials) guidance for reporting trials findings.  Adherence to 
the CONSORT statement would ensure that all outcomes are reported in full and all pre-specified 
outcomes are defined and reported.   
 
Many outcomes were not mentioned in trial reports meaning that clinical judgement was needed to 
decide whether the outcome of interest was likely to have been measured for a particular trial. A 
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limitation of this study was that we did not contact trialists to determine whether outcomes were 
measured if they were not mentioned although any uncertainties in classifications were confirmed 
by contact with review authors. Our decision not to contact trialists in this study was a pragmatic 
one. The most recent trial published for inclusion in this study was published over five years ago 
(median publication date 1999), meaning that there would be obvious difficulties in locating the 
majority of trialists. Nevertheless, the reliability of systematic reviews can be improved if more 
attention is paid to outcome data missing from the source trial reports. If data are missing, 
reviewers should be encouraged to at least attempt to contact the trialists or study sponsors to 
confirm whether the outcome was measured and analysed and, if so, obtain the results and update 
the review meta-analysis accordingly with the newly obtained data. Reviewers should also be 
encouraged to complete the Cochrane risk of bias tool. A new version the Cochrane risk of bias 
tool which includes a section on ‘bias in selection of reported result’ which is informed by the 
ORBIT study and is set to be launched in 2014 [21]. If obtaining outcome data is not feasible or 
successful then rather than do nothing, review authors are encouraged to apply a sensitivity 
analysis to assess the impact of outcome reporting bias on an individual review.  
 
The multivariate meta-analysis approach offers one such sensitivity analysis to reduce the potential 
impact of outcome reporting bias when there is missing trial data for many review outcomes. Our 
recommendation to reviewers would be to use the multivariate meta-analysis approach if, as in the 
Auranofin example, reasonable correlation estimates between outcomes are available. If estimates 
from IPD are not available then, one could also consider clinical or biological reason to inform the 
correlation, or consider sensitivity analyses over a range of sensible values [9]. For example, in the 
rheumatoid arthritis case study, we would hypothesise that the relationship between the number of 
tender joints has a positive correlation with pain (more tender joints would imply more pain), 
although the strength of the correlation may be more difficult to judge. There is a need for a central 
repository for individual participant data from trials [22]. This would not only greatly reduce the 
amount of missing data from reviews and reduce the possibility of ORB but also provide review 
authors with the means to obtain reliable within-study estimates of correlations (also for use in 
studies where this information is not available) should an analytical technique for adjusting a meta-
analysis be required. If one is not confident about the correlations between outcomes, then other 
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univariate sensitivity approaches under an assumed model for selective reporting could be applied 
to each outcome, for example the method performed by Copas et al. [1].   
 
The Auranofin example was used to demonstrate the MVMA approach for two reasons.  Firstly 
high-risk ORB classifications were awarded to at least one trial for tender joints count, pain, 
physician global and acute phase reactant.  Secondly, we observed potentially important statistical 
and clinical differences when comparing the treatment estimates between MVMA with univariate 
meta-analysis. In some instances the differences between the univariate and MVMA results is 
minimal; this may result when there is not much missing outcome data from the reviews or ORB 
suspicion is low [10].  The results to the application of the MVMA approach to all other rheumatoid 
arthritis reviews where an ORB assessment was considered in this study is available from the 
corresponding author on request. When applying the MVMA method to the Auranofin review, we 
choose to explore what happens when we specify both fixed and random effect models as we 
wanted to demonstrate the MVMA method using both model specifications. However, in practice, 
the choice of a fixed effect or a random effect model should be specified in the review protocol.  
Application of the multivariate meta-analysis approach to the Auranofin example has demonstrated 
a change in the treatment estimates between univariate and multivariate meta-analysis. High risk 
ORB classifications were awarded to at least one trial for tender joints count, pain, physician global 
and acute phase reactant. When we applied a multivariate meta-analysis (fixed or random), the 
pooled effect estimates moved towards the null for tender joints, swollen joints (fixed only), pain 
(random only), physician global (fixed only), patient global (fixed only) and acute phase reactant 
(fixed only).  This shift in direction of the treatment effect is suggestive that ORB maybe an issue 
for these outcomes. When the shift in treatment effects estimate is in the opposite direction then 
the impact of ORB is likely to be minimal.   
 
A previous study, which compared univariate meta-analysis with multivariate meta-analysis, led the 
authors to conclude that the choice between univariate and multivariate meta-analysis had unclear 
or limited practical importance [13]. Though this may often be the case, our evaluation suggests 
that multivariate meta-analysis approach may be especially relevant to adjust for outcome reporting 
bias when there is missing trial data for many review outcomes. Therefore our recommendation to 
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reviewers would be to use the multivariate meta-analysis approach if, as in the Auranofin example, 
reasonable correlation estimates between outcomes are available and ORB is a genuine concern.  
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Table.1  The Outcome Reporting Bias in Trials (ORBIT) study classification for missing or 
incomplete reporting in reports of randomized controlled trials 
Description Level of 
reporting 
Risk of 
bias 
Clear that the outcome was measured and analysed 
A Trial report states that outcome was analysed but only reports that result was not 
significant (typically stating p-value>0.05). Partial 
High 
Risk 
B Trial report states that outcome was analysed but only reports that result was 
significant (typically stating p-value<0.05). Partial No Risk 
C Trial report states that outcome was analysed but insufficient data were presented for the trial to be included in meta-analysis or to be considered to be fully tabulated. Partial 
Low 
Risk 
D Trial report states that outcome was analysed but no results reported. None High Risk 
Clear that the outcome was measured 
E Clear that the outcome was measured. Judgment says outcome likely to have been analysed but not reported because of non-significant results. None 
High 
Risk 
F Clear that the outcome was measured. Judgment says outcome unlikely to have been analysed. None 
Low 
Risk 
Unclear whether the outcome was measured 
G Not mentioned but clinical judgment says likely to have been measured and 
analysed but not reported on the basis of non-significant results. None 
High 
Risk 
H Not mentioned but clinical judgment says unlikely to have been measured at all. None Low Risk 
Clear that the outcome was not measured 
I Clear that the outcome was not measured. NA No Risk 
Risk of bias arising from the lack of inclusion of non-significant results when a trial was excluded from a meta-
analysis or non-fully reported in a review because the data were unavailable. 
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Table 2:  Clinical trials assessed for outcome reporting bias (n=155 trials) 
Classification 
Rheumatoid Arthritis Core Set of Outcomes 
 
TOTAL (%)d 
 
Tender 
Joints 
Swollen 
Joints Pain 
Patient 
Global 
Physician 
Global Function APR 
RD 
< 52 
weeks 
≥ 52 
weeks 
A 3 4 1 3 2 1 4 2 2 20 (1.8) 
B 1 1 0 0 1 0 0 0 0 3 (0.3) 
C 21 18 17 20 18 23 34 1 2 153 (13.7) 
D 2 1 6 6 7 7 5 2 2 36 (3.2) 
E 17 15 17 20 19 7 13 2 0 108 (9.7) 
F 9 9 8 7 6 7 8 0 0 54 (4.8) 
G 4 11 20 15 18 6 3 5 6 83 (7.4) 
H 1 3 11 11 16 13 3 81 0 58 (5.2) 
I 0 0 0 0 0 0 0 4 0 0 (0.0) 
Fully 
reported 97 93 75 73 68 91 85 25 21 603 (54) 
Total 155 155 155 155 155 155 155 122 33 1118 
TOTAL 
Missing Data 
(A-I) (%)a 
58 
(37.4) 
62 
(40.0) 
80 
(51.6) 
82 
(52.9) 87 (56.1) 
64     
(41.3) 
70 
(45.2) N/A
b 12 
(36.4)c  
APR: Acute Phase Reactant; RD: Radiological Damage. 
 
a The denominator used is the total number of trials where an assessment is possible (155). 
 
b Not applicable: OMERACT recommends outcome only applicable if follow-up > 52 weeks. 
 
c The denominator used is the total number of trials where an assessment is possible and the follow-up is greater than 52 weeks (33) . 
 
d The denominator used is 1118.  That is the total number of data points if all 155 trials reported on all seven core outcomes (TJC, SJC, Pain, 
Pat. Global, Phy.Global, Function, APR) plus the 33 trials that should have also measured and reported on RD due to a follow-up greater than 
52 weeks (i.e. (155*7) + (33*1) = 1118).  The numerator also excludes the assessment of RD for trials less than 52 weeks.   
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Table 3: Meta-analysis results for the Auranofin dataset 
      
Univariate meta-analysis Multivariate meta-analysis 
Mean 
Diff. † S.E.
 ††
 
p-value 95% C.I. ††† Mean Diff. S.E.
 †
 
p-value 
 95% C.I. †† 
  UFMA MFMA 
Y1 -3.759 0.666 <0.001*** -5.064; -2.453 -3.225 0.561 <0.001*** -4.324; -2.126 
Y2 -0.290 0.608 0.634 -1.482; 0.902 -0.047 0.559 0.933 -1.143; 1.049 
Y3 -4.681 0.974 <0.001*** -6.589; -2.772 -4.998 0.565 <0.001*** -6.105; -3.891 
Y4 -0.368 0.081 <0.001*** -0.527; -0.210 -0.275 0.062 <0.001*** -0.395; -0.154 
Y5 -0.409 0.120 0.001** -0.645; -0.173 -0.244 0.061 <0.001*** -0.363; -0.125 
Y6 -0.130 0.071 0.066 -0.268; 0.008 -0.160 0.055 0.004** -0.268; -0.052 
Y7 -9.040 1.592 <0.001*** -12.159; -5.920 -8.723 1.540 <0.001*** -11.741; -5.705 
  
URMA MRMA 
Y1 -3.822 0.921 <0.001*** -5.627; -2.016 -3.621 0.967 <0.001*** -5.516; -1.727 
Y2 0.148 1.181 0.900 -2.168; 2.463 0.408 1.166 0.726 -1.877; 2.693 
Y3 -4.681 0.974 <0.001*** -6.589; -2.772 -4.438 1.065 <0.001*** -6.525; -2.351 
Y4 -0.392 0.207 0.058 -0.797; 0.014 -0.394 0.253 0.120  -0.891; 0.102 
Y5 -0.409 0.120 0.001** -0.645; -0.173 -0.429 0.279 0.124 -0.976; 0.118 
Y6 -0.130 0.071 0.066 -0.268; 0.008 -0.208 0.108 0.054 -0.420; 0.003 
Y7 -9.788 3.252 0.003** -16.162; -3.414 -10.259 3.221 0.001*** -16.572; -3.946 
Y1: Tender Joints Count;  Y2: Swollen Joints; Y3: Pain; Y4: Physician Global; Y5: Patient Global; Y6: Function; Y7: Acute Phase 
Reactant. 
† Mean Diff.: Mean Difference 
†† S.E.: Standard Error of summary treatment effect estimate.      
††† C.I.: Confidence Interval 
*p-value<0.05; **p-value<0.005; ***p-value<0.001 
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Figure.1: Flow diagram of reviews eligibility and assessment of randomised controlled trials 
within reviews 
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        Number of rheumatoid arthritis reviews 
identified on the Cochrane Library 
[Issue 9, 2012] (n=56) 
Exclusions (n=35): 
 Non-Pharmacological Interventions:  20 
 Symptom Modifying Anti-Rheumatic Drugs: 13 
 Overviews: 1 
 Safety: 1 
 
Reviews requiring no further assessment (n=0) 
 
Further assessment required (n=21) 
 
 DMARD: 12 
 Biologics: 8 
 Glucocorticoids: 1 
 
         Review assessed (n=21) 
Number of trials (n=172) [21 reviews] 
 
 DMARD:  108 
 Biologics:  47 
 Glucocorticoids: 17 
 
Trials fully reporting all core 
outcomes
*
 (n=21): 
 
 All core outcome data included in 
the review (n=10) 
 Core outcome data not fully 
reported in the review (n=11) 
 
Trials assessed (n=155) 
 
 DMARD:                  94 
 Biologics:   45 
 Glucocorticoids:  16                 
 
Trials not fully reporting on all core outcomes 
(n=134) 
 
 DMARD:  88 
 Biologics:  31 
 Glucocorticoids: 15 
 
Could not assess trial reports further (n=17) 
 
 Non-English:   10 
 Trial reports unavailable:  7
#
 
#
5 were excluded studies 
 
Trials assessed for outcome reporting bias (n=134) 
 
